Seeking Alpha

nova » Comments » Single Comment |

  • Ustekinumab PDUFA Could Kick Start Medarex Revival [View article]
    A company's enterprise value is a bogus number invented by the Wall-Street feeble-minded geniuses.

    IMO, in the past, Medarex always had very poor and extremely corrupt management. Being familiar with Bristol's clinical capabilities, BMY is looser. It almost killed ImClone. Only Merck KGaA Erbitux clinical program saved ImClone and converted Erbitux into a super blockbuster.

    It is pity that for so many years, Medarex was unable of developing and marketing ant single drug.
    Nov 29 14:31 pm |Rating: 0 0
All Comments by nova »
Comments by Ticker
AA, AAPL, ABB, ABT, ABX, ACI, ACOR, ADM, AEM, AGQ, AGU, AHBIF.PK, AIG, AKP, ALKS, ALTH, ALXN, AMAT, AMGN, AMLN, AMZN, ANDE, ANF, APOL, ARIA, ARNA, AUY, AVAV, AXP, AZN, AZO, BAC, BAL, BAYRY.PK, BBH, BBT, BCS, BDX, BHI, BIIB, BIK, BIOD, BK, BKF, BLK, BMRN, BMY, BP, BRK.A, BRK.B,
nova is a
Top 100 Commentor
569 comments
Rating: 1048 (1780 - 732 )